No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Nerivio Wearable Migraine Therapeutic Now Eligible for Insurance Coverage through UpScript’s Telemedicine Platform

Editor: What To Know

  • “We believe this is a unique way for migraine headache patients to try a great device in a convenient, affordable way through a telemedicine visit on the UpScript platform.
  • “At UpScript, we are pleased to be providing US patients the opportunity to try Nerivio, a unique prescribed therapeutics device which is now available for reimbursement,” added UpScript CEO Peter Ax.
  • This service connects any patient with a trained healthcare provider and, if they secure a prescription, a quick path to receiving their device, anywhere in the United States.

April 12, 2021

Nerivio (FDA-authorized) prescribed wearable for the acute treatment of migraine is now eligible for insurance coverage through the UpScript direct-to-patient telemedicine platform.

“It is our mission to make Nerivio accessible to everyone who experiences migraine episodes,” said Theranica CEO Alon Ironi. “We appreciate the efforts UpScript made to make Nerivio available and covered through its advanced telemedicine platform.

People with migraine need rapid, affordable access to safe and effective therapies, and this is exactly what they can get using UpScript. This service connects any patient with a trained healthcare provider and, if they secure a prescription, a quick path to receiving their device, anywhere in the United States.”

Nerivio’s list price (Wholesale Acquisition Price, or WAC) is $599 for a 12-treatment unit. The Nerivio Patient Savings Program and reimbursement hub implementation enables Theranica to offer eligible patients with health insurance a co-pay as low as $10, depending on specific plan coverage. Nerivio is also covered by United States Veterans Administration (VA) system health insurance.

“At UpScript, we are pleased to be providing US patients the opportunity to try Nerivio, a unique prescribed therapeutics device which is now available for reimbursement,” added UpScript CEO Peter Ax. “We believe this is a unique way for migraine headache patients to try a great device in a convenient, affordable way through a telemedicine visit on the UpScript platform.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy